arrow
M

Michael A. Horberg

University of California San Francisco
H指数:59
被引数:1.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The effect of hypothetical interventions to limit weight gain on incident type 2 diabetes mellitus among people with HIV initiating antiretroviral therapy in the United States, 2012-2021

2012-2021年,假设干预措施限制体重增加对美国开始抗逆转录病毒治疗的HIV感染者中2型糖尿病发病的影响

2026-10-140
PRE
Brief Report: Mammogram Rates Among Women With and Without HIV in a Large Integrated Health Care System

简报:大型整合医疗保健系统中HIV感染与未感染女性的乳腺X光检查率

2026-07-010
PRE
Characterizing STI testing and diagnosis disparities between Asian people with HIV and other racial/ethnic subpopulations in Washington, District of Columbia: a longitudinal analysis of the DC Cohort, 2018-2023

评估华盛顿哥伦比亚特区亚洲裔HIV感染者与其他种族/族裔亚群在性传播感染检测和诊断方面的差异:基于DC队列2018-2023年的纵向分析

2026-01-010
PRE
Near real-time surveillance and tree-based data mining to assess the safety of respiratory syncytial virus vaccines in older adults in the vaccine safety datalink

近实时监测和基于树的数据挖掘方法,用于评估疫苗安全数据链中老年人群呼吸道合胞病毒疫苗的安全性。

Vaccine
IF3.5
2025-10-240
PRE
Prevalence, incidence, and risk factors for dermatologic conditions in people with HIV in the modern antiretroviral era: A cohort study in Washington, DC

在当代抗逆转录病毒治疗时代,HIV感染者中皮肤疾病的患病率、发病率和危险因素:一项在华盛顿特区进行的队列研究

2025-10-140
PRE
Risks for adverse events by sex and age after prescription opioid dose reduction

性别和年龄对处方阿片类药物剂量减少后不良事件风险的影响

2025-09-060
PRE
Direct-Acting Antiviral Initiation Among People With Hepatitis C Virus (HCV) and HIV on Antiretroviral Therapy in the United States and Canada: Factors Driving the HCV Treatment Gap

直接抗病毒药物启动治疗在患有丙型肝炎病毒(HCV)和人类免疫缺陷病毒(HIV)且接受抗逆转录病毒治疗的患者中的使用(美国和加拿大):导致HCV治疗差距的因素

2025-08-040
OAAI
Changes in the Prevalence of Non-AIDS Conditions Among Hospitalized Persons With Human Immunodeficiency Virus (HIV) in the United States and Canada, 2008-2018
2025-04-010
PRE